Skip to content
Open access

Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis

Nov 2026 · Advancement of science · 0 citations · 55 references
Medicine

TL;DR

This work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.

Abstract

ABSTRACT The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae (F. duncaniae) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae. We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.

Read PDF

Similar papers

Open access Oct 2026

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis

ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin‐22 (IL‐22) as a potential treatment approach faces challenges in the clinical translation due to off‐target risks associated with systemic delivery. To address this limitation, we develope...

C. Ji, Yan Fang, Shen Zhang et al. · 0 citations
Open access Oct 2026

Curcumin alleviates metabolic dysfunction-associated steatotic liver disease via gut microbiota-dependent epigenetic alterations

A novel gut-liver axis is revealed in MASLD pathogenesis, demonstrating that Cur alleviates hepatic steatosis by targeting the microbiota-KYN-AHR-H3K27ac-Cebpb epigenetic axis, positioning Cur supplementation and KYN modulation as promising therapeutic strategies for MASLD intervention.

Yong Zhu, Jin-Hu Ma, Dan-Hong Wang et al. · 0 citations
Review Open access Sep 2026

Targeting gut dysbiosis: a new frontier in MASLD management

This narrative review explores the mechanistic pathways through which an altered gut microbiome contributes to MASLD, by specifically emphasizing intestinal barrier disruption, endotoxemia, altered bile acid metabolism, and SCFA imbalance.

Shweta Sharma, Arun Pachauri, Harsha Nagar et al. · 0 citations
Open access Nov 2026

Dual Gut Microbiota‐Dependent Mechanisms Underlying the Anti‐Atherosclerotic Effect of Tilianin

ABSTRACT Tilianin (Til), a flavonoid from Dracocephalum moldavica L. and Agastache species, exerts potent anti‐atherosclerotic effects via gut microbiota‐mediated mechanisms. In atherosclerotic mice, Til dose‐dependently reduced plaque burden and enhanced plaque stability by reducing necrotic cores and increasing colla...

Xu-Li Ruan, Ru-Yue Liu, Wen-Jiang Cao et al. · 0 citations
Open access Oct 2026

Gut Microbiota‐Dependent Tryptophan Metabolism Drives the Therapeutic Effects of Baitouweng Tang in Colitis via the AhR Pathway

ABSTRACT With dysregulation of the gut microbiota and its metabolic byproducts playing a pivotal role in inflammatory bowel disease (IBD) pathogenesis. Baitouweng Tang (BTWT), a traditional herbal formulation, has long been employed to treat gastrointestinal disorders and shows promising potential in the management of...

Chun Niu, Yong-Li Hua, Jian-Guo Kang et al. · 0 citations
Open access 2026

Development and clinical validation of Lactobacillus helveticus BGRA43: An innovative probiotic approach for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is closely associated with metabolic disorders such as obesity, insulin resistance, and dyslipidemia. Its prevalence continues to increase, and current management strategies rely primarily on lifestyl...

K. Jončić Savić, A. Teofilović, M. Vratarić et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.